Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Randomized, Double-Blind, Dose-Finding, Phase II Study of Prasugrel in Japanese Patients Undergoing Elective Percutaneous Coronary Intervention.

Journal of atherosclerosis and thrombosis - 1 Jan 2015

Kimura Takeshi, Isshiki Takaaki, Ogawa Hisao, Yokoi Hiroyoshi, Yamaguchi Tetsu, Ikeda Yasuo

Abstract excerpt

AIM: Prasugrel is a novel platelet P2Y12 receptor blocker with a faster onset of action and greater platelet inhibition with less response variability than clopidogrel. Our objective was to determine the optimal prasugrel dose in Japanese patients undergoing elective percutaneous coronary intervention (PCI) with respect to the incidence of bleeding and platelet inhibition. METHODS: A total of 422 patients were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2C19
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemorrhage

Share to Myocardial Infarction

Share to Percutaneous Coronary Intervention

Share to Platelet Aggregation

Share to Platelet Aggregation Inhibitors

Share to Prasugrel Hydrochloride

Source

Identifiers

PMID: 25737192
DOI: 10.5551/jat.26013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Randomized, Double-Blind, Dose-Finding, Phase II Study of Prasugrel in Japanese Patients Undergoing Elective Percutaneous Coronary Intervention.PMID 25737192Read ↗

Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.Semantic proximity Read ↗

Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease.Semantic proximity Read ↗

The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers.Semantic proximity Read ↗

A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.Semantic proximity Read ↗

Safety considerations with the use of platelet inhibitors for elderly patients with non-ST- elevation acute coronary syndrome.Semantic proximity Read ↗

Pre-procedural platelet reactivity after clopidogrel loading in korean patients undergoing scheduled percutaneous coronary intervention.Semantic proximity Read ↗

Guided antiplatelet therapy with P2Y12 antagonists in patients undergoing percutaneous coronary intervention: 3 systematic reviews with meta-analyses of randomized controlled trials with homogeneous designSemantic proximity Read ↗

miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome.Semantic proximity Read ↗

Guided Anti-P2Y12 Therapy in Patients Undergoing PCI: Three Systematic Reviews with Meta-analyses of Randomized Controlled Trials with Homogeneous Design.Semantic proximity Read ↗

Ticlopidine with Ginkgo Biloba extract: a feasible combination for patients with acute cerebral ischemia.Semantic proximity Read ↗

Initial ticagrelor monotherapy strategy is effective and safe in patient with high bleeding risk after percutaneous coronary intervention: series case reports and literature reviewSemantic proximity Read ↗

Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.